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Abstract
Gastrointestinal luminal endoscopy is of paramount 
importance for diagnosis, monitoring and dysplasia 
surveillance in patients with both, Crohn’s disease and 
ulcerative colitis. Moreover, with the recent recognition 
that mucosal healing is directly linked to the clinical 
outcome of patients with inflammatory bowel disorders, 
a growing demand exists for the precise, timely and 
detailed endoscopic assessment of superficial mucosal 
layer. Further, the novel field of molecular imaging 
has tremendously expanded the clinical utility and 
applications of modern endoscopy, now encompassing 
not only diagnosis, surveillance, and treatment but 
also the prediction of individual therapeutic responses. 
Within this review, we describe how novel endoscopic 
approaches and advanced endoscopic imaging 
methods such as high definition and high magnification 
endoscopy, dye-based and dye-less chromoendoscopy, 
confocal laser endomicroscopy, endocytoscopy and 
molecular imaging now allow for the precise and 
ultrastructural assessment of mucosal inflammation and 
describe the potential of these techniques for dysplasia 
detection. 
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Colitis associated cancer; Confocal laser endomicroscopy; 
Endocytoscopy; Molecular imaging
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Gastrointestinal luminal endoscopy is of 
paramount importance for diagnosis, monitoring 
and dysplasia surveillance in patients with Crohn’
s disease and ulcerative colitis. Within this review, 
we describe how novel endoscopic approaches and 
advanced endoscopic imaging methods such as high 
definition imaging, high magnification endoscopy, 
dye-based and dye-less chromoendoscopy, confocal 
laser endomicroscopy, endocytoscopy and molecular 
imaging now allow for the accurate and highly resolved 
assessment of mucosal inflammation on the cellular 
level and describe the potential of these techniques for 
dysplasia detection.
Tontini GE, Rath T, Neumann H. Advanced gastrointestinal 
endoscopic imaging for inflammatory bowel diseases. World J 
Gastroenterol 2016; 22(3): 1246-1259  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v22/i3/1246.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v22.i3.1246
INTRODUCTION
Inflammatory bowel diseases (IBD) comprises the two 
major forms Crohn’s disease (CD) and ulcerative colitis 
(UC) both of which are immunopathogenic complex 
diseases in which, on the basis of a genetic susceptibility 
host, an excessive mucosal immune response towards 
the complex enteric microbiota plays a role for the 
initiation and perpetuation of intestinal inflammation[1-4]. 
Recent studies estimate that approximately 1.2 
million people in the US and 3.7 million people in 
Europe suffer from IBD and in most parts of the world 
IBD incidence rates increase over time[5,6]. With its 
profound involvement in diagnosis of UC and CD, in 
monitoring response to anti-inflammatory therapy 
as well as in dysplasia surveillance, gastrointestinal 
luminal endoscopy is of paramount importance for the 
management of IBD patients.
In the recent past, mucosal healing has increasingly 
been recognized as a key clinical treatment goal in 
IBD patients. Since it has been shown that complete 
mucosal healing is one of the most crucial aspects that 
predicts sustained clinical remission and resection-
free survival of patients[7], the precise and detailed 
assessment of the superficial mucosal layer in 
real-time becomes more important than ever for 
the medical management of IBD patients. In this 
context, advanced endoscopic imaging techniques 
including dye-based and dye-less chromoendoscopy, 
endocytoscopy and confocal laser endomicroscopy 
have been shown to allow precise, ultrastructural and 
even microscopic characterization of the inflammation 
within the luminal gastrointestinal tract in real time, 
thereby tremendously facilitating the diagnosis of 
IBD and the direct evaluation of response to medical 
therapy. 
Apart from assessing the degree and extent of 
inflammation, regular surveillance endoscopies for 
dysplasia screening is another important aspect in 
the management of IBD patients. Several studies 
documented that the chronic inflammatory stimulus 
associated with IBD confers an increased risk for 
developing colitis associated cancer (CAC) in both, 
UC and CD patients[8] and the individual colon 
cancer risk mainly depends on disease duration, 
severity and anatomic extent of the disease[9-13]. 
Due to the close association between disease duration 
and the development of CAC, current European and 
US guidelines recommending regular surveillance 
endoscopy starting 6 to 8 years after first manifes-
tation of the disease[14,15] and a large number of case 
series[16-19] and case-control studies[20-22] provided 
evidence of the clinical benefit of surveillance colono-
scopy for IBD patients. However, at the same time 
routine white-light endoscopic examinations is 
limited for the accurate identification of dysplasia 
and intraepithelial neoplasia[23] and at the same 
time, random biopsies have a low yield for dysplasia 
detection[23,24].
While several reports have shown that traditional 
dye-based chromoendoscopy (DBC) with targeted 
mucosal biopsies is superior for dysplasia detection 
in IBD patients[23,24], it is a time- and cost intensive 
procedure that requires a certain level of expertise 
and training. These confinements associated with 
DBC have led to the rapid evolvement of novel 
advanced endoscopic imaging techniques such as 
digital [i.e., Fujinon Intelligent Color Enhancement 
(FICE), i-scan, Storz Professional Image Enhancement 
Systems (SPIES)] or optical [i.e., Narrow band 
imaging (NBI), Compound band imaging (CBI)] dye-
less chromoendoscopy which offer the advantage 
of enhancing mucosal vascular and mucosal surface 
pattern morphology by just pushing a button on the 
handle of the endoscope thereby potentially reducing 
time and costs associated with conventional dye-based 
chromoendoscopy[25,26].
Within this article, we review the current literature 
on the role of advanced endoscopic imaging techniques 
such as high-definition and optical magnification 
endoscopy, dye-based and dye-less chromoendoscopy, 
confocal laser endomicroscopy and endocytoscopy 
for the assessment of the extent and degree of 
inflammation and the surveillance of colitis-associated 
cancer. Further, we provide an outlook on how first 
studies have utilized molecular imaging to visualize 
single molecular structures and also to stratify patients 
according to the expression of certain molecular 
targets, thereby allowing to make predictions of 
responses to medical therapies.
HIGH-DEFINITION AND OPTICAL 
MAGNIFICATION ENDOSCOPY
The chips used in current high-definition (HD) endo-
scopes produce signal images with resolutions that 
range from 850000 pixels to more than 1 million pixels 
and the general definition of a HD image (or display) is 
one with more than 650 to 720 lines of resolution[27,28]. 
In order to obtain true HD images, all components 
utilized (i.e., endoscope video chip, processor, monitor, 
transmission cables) have to be HD capable. As 
compared to standard definition (SD) video chips, HD 
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chips have a considerably lower light sensitivity due 
to the smaller size of their pixels, thereby requiring a 
strong light source which is typically a 300 watt Xenon 
lamp or a laser source[27]. 
As shown in a recent meta-analysis of over 4000 
non-IBD patients comparing the diagnostic yield of 
colonic polyps between high-definition and standard 
white-light colonoscopy, HD exhibited only a marginally 
increased yield for the detection of colorectal polyps 
of 3.5% compared to SD and the number needed to 
treat was calculated to be 28[29]. 
However, while HD offers only an incremental 
increase for the detection of sporadic adenomas, its 
relevance for the detection of dysplastic changes in IBD 
is remarkable. In patients with IBD, dysplastic lesions 
often develop as flat lesions within the mucosa rather 
than as protruding into the intestinal lumen. As shown 
in a retrospective cohort study based on 369 subjects 
with long-standing colonic IBD, HD colonoscopy could 
detect significantly more adenomas especially within 
flat or right-sided lesions, as compared to standard 
definition white light colonoscopy[30]. Overall, the 
adjusted prevalence ratio of detecting dysplastic 
lesions on targeted biopsies was calculated as 2.99 for 
HD colonoscopy[30]. 
Optical magnification endoscopy 
Otpical magnification utilizes a movable lens to vary the 
degree of magnification thereby allowing to magnify the 
mucosa of the gastrointestinal tract from 6-fold up to 
150-fold[31]. Since this magnification is based on an 
optical zoom, the image quality is maintained while 
zooming. In contrast to this optical magnification, 
electronic or digital magnification simply enlarges 
the image on the display, leading to decreased pixel 
density and decreased image quality[27]. In one of the 
earliest studies, optical magnification endoscopy has 
been shown to be able to differentiate true neoplasms 
from non-neoplastic colonic lesions by analyzing the 
mucosal pit pattern. Hence, as shown in this landmark 
trial, magnification endoscopy can provide an accurate 
and instantaneous prediction of the histology of 
colorectal tumorous lesions[31].
This observation in colorectal polyps has recently 
been extended to other neoplastic and non-neoplastic 
diseases in the upper and lower gastrointestinal 
tract, and was especially used in combination with 
dye-based chromoendoscopy[32-38]. In one of the 
earliest prospective randomized trials, Kiesslich and 
co-workers were able to show that methylene blue-
aided chromoendoscopy in combination with optical 
magnification not only allowed for a better assessment 
of the degree and extent of colonic inflammation 
compared to conventional colonoscopy, but also to 
detected significantly more intraepithelial neoplasia 
compared to standard white-light endoscopy[24]. 
Consistent with these observations, in a prospective 
trial on 350 patients with long-standing UC, signi-
ficantly more intraepithelial neoplastic lesions were 
detected by magnification chromoendoscopy compared 
with 350 disease-matched controls that received 
conventional endoscopy. Importantly, of the 67 lesions 
with intraepithelial neoplasia that were found, 53 (79%) 
were detected using magnification chromoendoscopy 
alone. In addition, magnification endoscopy was able 
to predict neoplastic and non-neoplastic mucosal 
changes with high overall accuracy[34]. Several lines 
of evidence now support the concept of enhanced 
dysplasia detection with magnification (chromo)-
endoscopy and it appears that especially the high-
resolution and high magnification visualization of 
the pit and vascular pattern is a key component and 
of paramount importance for the identification of 
dysplastic areas in IBD[34,39-43].
Apart from dysplasia detection, high magnification 
chromoendoscopy has been utilized for the assessment 
of disease extent and disease severity in IBD. In one 
of the earliest pilot study, magnification endoscopy 
was utilized to grade the rectal network pattern and 
cryptal opening in 41 patients with mild to moderate 
UC. When both features were combined, patients 
with visible network pattern and cryptal opening had 
a lower clinical activity and lower grade of histologic 
inflammation compared to patients in which both 
findings could not be visualized. Therefore, these 
data provide evidence that magnification endoscopy 
is capable of predicting the histologic degree of 
inflammation[44]. In a prospective trial on 113 patients 
with quiescent UC, Nishio and co-workers studied the 
role of magnification endoscopy for predicting the 
clinical course of disease[45]. The authors classified 
the rectal pit pattern appearance into four groups 
according to its irregularity: grade 1, small, round, 
and regularly arranged pits; grade 2, rather large, 
oval pits, somewhat irregular in arrangement; grade 
3, pits various shapes and sizes, and irregularly 
arranged; grade 4, dispersed pits varying in mor-
phology, associated with small erosions. Using this 
classification, the authors found that magnification 
endoscopy grading correlated to histopathological 
findings and acts as a significant predictor of relapse 
with a relative risk of 2.0[45]. Further, magnification 
endoscopy calculated a relapse risk of 60% in the 
following 12 mo in patients who had a grade 4 rectal 
pit pattern, but who had only mild or no endoscopic 
features of disease activity at the time of endoscopy[45]. 
Consistent with these data, Hurlstone et al[35] found 
a good correlation between the Saitoh criteria for 
magnification imaging and Matts’ histopathological 
criteria in a prospective trial including 325 UC patients. 
In a biphasic examination, all colonic segments were 
first inspected with conventional white-light endoscopy, 
followed by high magnification chromoendoscopy. It 
has been shown, that magnification imaging results in 
a significantly better prediction of disease extent than 
conventional endoscopy.
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of mucosal inflammation and dysplasia in ulcerative 
colitis, Kiesslich and co-workers directly compared DBC 
and conventional colonoscopy in a large cohort of UC 
patients. Importantly, DBC with methylene blue not only 
permitted a more accurate diagnosis of the extent and 
severity of the inflammatory activity in UC compared 
with conventional colonoscopy, but also significantly 
improved the early detection of intraepithelial neoplasia 
and CAC[24]. Another “back-to-back” study evaluated 
pancolonic indigo carmine staining 0.1% for the 
detection of UC-associated dysplasia[23]. As shown in 
this study, DBC with indigo carmine led to a higher 
dysplasia detection rate while at the same time reducing 
the total amount of biopsies[23]. Consistent with these 
results, another prospective trial also included patients 
with Crohn’s colitis (CC), and similarly, in both UC and 
CC, targeted biopsies after dye spraying (methylene 
blue) detected significantly more dysplastic lesions 
than random biopsies[55]. Those results have been 
summarized and quantified in a recent meta-analysis of 
six randomized controlled trials, verifying that dye-based 
chromoendoscopy has a medium to high sensitivity and 
a high diagnostic accuracy for detection of dysplastic 
lesions in UC[56]. In its totality, this profound evidence 
on the superiority of DBC for the detection of colitis-
associated neoplasia, together with the knowledge 
of a cumulative colorectal cancer (CRC) risk in UC 
patients of 18% after 30 years of disease[10], have led 
to the recommendation to perform chromoendoscopy 
with targeted biopsies as the surveillance proce-
dure of choice in IBD patients in US and European 
guidelines[14,15,47,48]. Furthermore, international multi-
disciplinary unifying consensus guidelines, the so-
called SCENIC (Surveillance for Colorectal Endoscopic 
Neoplasia Detection and Management in Inflammatory 
Bowel Disease Patients: International Consensus 
Recommendations) recommendations, have been 
launched just recently. In these guidelines, performance 
of pancolonic chromoendoscopy with indigo carmine 
or methylene blue is the modality of choice for IBD 
surveillance, and also high-definition colonoscopy is 
preferred over standard white-light colonoscopy[57,58]. 
While the superiority of DBC for dysplasia detection 
during IBD surveillance is undeniable, DBC is in 
general a time- and cost-consuming procedure, both 
factors working against its routine implementation 
into daily routine clinical practice. In terms of costs 
associated with DBC, a recent study evaluated 
whether DBC is cost-effective for colorectal cancer 
surveillance in UC patients and found that DBC with 
targeted biopsies is not only more effective but also 
less costly compared to conventional white-light 
endoscopy with four quadrant random biopsies taken 
every 10 cm[59]. Thereby, from this study it appears 
that the cost-savings associated with targeted biopsies 
outcompetes the costs associated with increased time 
and materials required for DBC and targeted biopsies. 
In terms of additional time requirements, it has 
been shown that, even in expert hands, pancolonic 
CHROMOENDOSCOPY
Chromoendoscopy enhances the mucosal architecture 
and/or submucosal microvasculature by the use of 
various dyes (Dye-based chromoendoscopy, DBC) 
or endoscopic optical and computer-based color 
programs (Dye-less chromoendoscopy, DLC). This 
contrast enhancement of the mucosal layer results in 
the improved detection of lesions that are often subtle 
or even nearly invisible at conventional white-light 
endoscopy. 
DBC uses different dye agents which are divided 
into absorptive agents (Lugol solution, methylene 
blue, toluidine blue, and cresyl violet), contrast agents 
(indigo carmine, acetic acid) and reactive staining 
agents (congo red, phenol red), all of which are mostly 
applied via standard spraying or plain biliary ERCP 
catheters[46]. As briefly mentioned above, DBC has 
been shown to improve detection of dysplasia in IBD, and 
chromoendoscopy is recommended as the preferred 
modality for surveillance in patients with colonic IBD 
by the British Society of Gastroenterology[47] and 
the European Crohn’s and Colitis organization[48]. 
However, DBC also requires increased efforts, skills, 
time, and costs. These confinements associated with 
the use of traditional dye agents have finally led to the 
development of dye-less chromoendoscopy techniques 
(DLC). 
DLC is further subdivided into optical chromo-
endoscopy (NBI, Olympus, Japan; CBI, Aohua Photo-
electricity, Shanghai, China) and digital chromoendoscopy 
(i-scan, Pentax, Tokyo, Japan; FICE, Fujifilm, Tokyo, 
Japan; SPIES, Karl Storz, Tuttlingen, Germany). Optical 
DLC utilizes optical filters within the light source of 
the endoscope to narrow the bandwidth of spectral 
transmittance, thereby enhancing and facilitating the 
visualization of blood vessels. In contrast, digital DLC 
uses digital postprocessing algorithms that reconstruct 
the endoscopic image from the video processor in real 
time, thereby resulting in an improved contrast of the 
mucosal capillary pattern and an enhancement of the 
mucosal surface pattern morphology[25,46].
Importantly, both optical and digital DLC are simple 
“push-of-a-button” techniques that are readily available 
during the endoscopic examination. Thus, compared 
to traditionally used dye-based chromoendoscopy, DLC 
theoretically offers the advantage of dye-enhanced 
mucosal imaging without the efforts in time and costs 
of applying contrast agents during the endoscopic 
examination. Further, data derived from the in vivo 
assessment of colorectal polyp histology impressively 
demonstrated that DLC can be readily learned even by 
“non-expert” endoscopists[49-51]. Hence, endoscopists 
with varying levels of experience can accurately 
use digital chromoendoscopy after a single training 
session[52,53] with comparable diagnostic accuracies 
between non-expert and expert endoscopists[54].
In one of the earliest prospective randomized 
trials on the relevance of DBC for the assessment 
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dye spraying requires 4 to 10 min additional time, 
resulting in a 30%-40% increase in total procedure 
duration[60,61]. Finally, DBC has some other potential 
limitations other than increase in costs and efforts: the 
dye does not coat the mucosa evenly and dye pooling 
can lead to difficult observation and interpretation. In 
addition, DBC cannot provide a detailed evaluation of 
the mucosal vascular pattern morphology, which is a 
critical component in the diagnosis of disease activity 
and dysplasia detection in IBD. 
In an attempt to overcome these potential limi-
tations and hurdles associated with the use of DBC, 
dye-less chromoendoscopy techniques have rapidly 
evolved in the recent past.
The first description of optical dye-less chromo-
endoscopy (DLC; i.e., NBI) for identification of colitis 
associated neoplasia was published in 2006. In 
this report on a 63-year-old man with longstanding 
ulcerative colitis and a previous history of dysplasia 
associated lesions or masses (DALM), it was shown for 
the first time that visualization of the pit pattern and 
the mucosal vascular pattern intensity by NBI might 
help in DALM detection and to discriminate dysplastic 
from non-dysplastic areas in ulcerative colitis[62]. 
As shown in this report, especially the capillary 
vasculature exhibited a higher vascular pattern and 
appeared darker on NBI in dysplastic lesions compared 
to adjacent normal mucosa[62]. Since then, various 
trials have studied the potential of NBI to assess the 
degree of mucosal inflammation and colitis associated 
preneoplastic and neoplastic changes. In one of the 
earliest prospective randomized trials, the accuracy 
of NBI for the detection of neoplasia in patients with 
longstanding ulcerative colitis was compared against 
standard colonoscopy[63]. In general, more suspicious 
lesions were found with NBI, however the sensitivity of 
NBI for neoplasia detection was similar to conventional 
white-light endoscopy[63]. Soon thereafter, the same 
group assessed the value of NBI for surveillance in UC 
in two other studies[64,65]. In these studies, pit pattern 
analysis of neoplastic lesions exhibited only a moderate 
accuracy for the prediction of histology[64]. Compared 
to high-definition endoscopy, NBI did not improve 
the detection of UC associated neoplastic lesions[65]. 
Subsequently, trials comparing NBI against dye-based 
chromoendoscopy for the detection of colonic dysplasia 
in IBD found no significant differences between both 
techniques for dysplasia detection[66,67].
Consistent with this, a recent meta-analysis of 
four studies comparing dye-based chromoendoscopy 
and NBI found a non-significant lower dysplasia 
detection rate with NBI[57,58]. The result of this meta-
analysis indicates that a meaningful benefit of NBI 
over chromoendoscopy is unlikely. However, at the 
same time the study also did not documented a 
benefit of chromoendoscopy over NBI and clearly, 
higher powered studies are needed to address 
this question[68,69]. Based on the above mentioned 
evidence, NBI is, at the moment, not recommended 
to replace dye-based chromoendoscopy for cancer 
surveillance in IBD patients[57,58]. 
Data on the relevance of digital chromoendoscopy 
for IBD surveillance are scare to date. First evidence 
that digital chromoendoscopy with FICE might be 
superior to white-light colonoscopy with standard 
definition for the detection of dysplastic lesions in UC 
comes from a prospective, randomized trial that was 
just recently presented at the ECCO 2015 meeting[70].
The role of dye-less chromoendoscopy to assess 
mucosal inflammation associated with IBD has also 
been studied. In one of the earliest reports, Kudo and 
colleagues analyzed the mucosal vascular pattern 
(MVP) in patients with asymptomatic or mildly active 
UC using NBI and HD white-light endoscopy[71]. The 
authors found that areas with obscure MVP on NBI 
exhibit increased numbers of acute inflammatory cell 
infiltrates, goblet cell depletion and basal plasmacytosis 
and that evaluation of the MVP with NBI yielded a 
more precise determination of acute microscopic 
inflammation in patients with quiescent UC[71]. The 
typical appearance of active UC and inactive, quiescent 
disease on NBI have been summarized by the same 
group of authors[72]. In addition to that, another pilot 
study on 14 IBD patients was able to demonstrate 
that areas that appear normal on WLE, but positive 
on NBI (as defined by a stronger capillary vascular 
pattern), exhibit an increased leukocyte infiltrate 
and a significantly increased microvessel density 
on immunohistology, thus providing first evidence 
that NBI might allow in vivo imaging of intestinal 
angiogenesis in IBD patients[73]. 
Data on the relevance of digital DLC for the 
assessment of mucosal inflammation in IBD patients 
are limited. To date, only one study evaluated FICE 
in IBD patients and showed that FICE is not helpful 
to improve the detection or delineation of ulcers 
and erosions in CD[74]. Just recently, a study on 78 
IBD patients that were randomized to receive either 
HD white-light endoscopy or HD endoscopy with 
i-scan, was able to demonstrate that i-scan allows a 
considerably improved prediction of disease extent and 
disease activity compared to white-light endoscopy 
(i-scan: 92% and 90% vs WLE: 49% and 54%)[75]. 
Of note, examination time was not different between 
WLE and i-scan, consistent with the idea that dye-less 
chromoendoscopy is a push-of-a-button technology 
that can be readily incorporated into the existing 
examination[75]. Although no studies have directly 
assessed the relevance of digital chromoendoscopy for 
the detection of colitis-associated neoplasia and cancer, 
it has been shown that HD endoscopy with i-scan can 
significantly detect more neoplastic lesions and more 
flat adenomas than standard resolution endoscopy[76] 
and is as precise as dye-based chromoendoscopy for 
the characterization of small colorectal lesions in non-
IBD patients[77]. Based on these results, data on the 
assessment of colitis associated dysplasia by digital 
DLC are eagerly awaited. 
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CONFOCAL LASER ENDOMICROSCOPY
Confocal laser endomicroscopy (CLE) can visualize 
structures at the (sub)cellular level[78], and since its 
introduction in 2003 CLE has emerged as a technique 
that can be utilized for precise histologic real time 
in vivo imaging of various diseases[79-83]. Technically, 
after topical (acriflavine hydrochloride, cresyl violet) 
or systemic (fluorescein sodium) administration of 
contrast agents, CLE emits a low power blue laser 
light onto the tissue, which is then reflected from 
the tissue and refocused on the detection system 
by the same lens, leading to microscopic imaging at 
1000-fold magnification in real time[81]. Currently, two 
different FDA-approved and CE-certified CLE devices 
are available[84]: (1) a probe based CLE system that 
can be advanced through the accessory channel of 
a standard endoscope (pCLE, Cellvizio, Mauna Kea 
Technologies, Paris, France); and (2) an integrated 
device where the CLE probe is integrated into the 
distal end of a high-resolution endoscope (“integrated”, 
iCLE; Pentax, Tokyo, Japan). Both pCLE and iCLE emit 
blue laser light with wavelength of 488 nm, and light 
reflection from the tissue is detected at wavelengths 
between 205 and 585 nm. The iCLE-system acquires 
images at a manually adjustable scan rate of 1.6 
frames/s with a resolution of 1024 × 512 pixels, or 
at 0.8 frames per second with a resolution of 1024 
× 1024 pixels. The depth of scanning and the laser 
power can be adjusted from 0 to 250 μm and from 0 
and 1000 μW, respectively. The optical slice thickness 
is 7 μm, with lateral and axial resolution of 0.7 μm 
and a confocal image field of view of 475 μm × 475 
μm.
The pCLE system utilizes separately available 
confocal probes, and specific probes for different 
indications throughout the entire gastrointestinal tract 
are available. Probe-based CLE utilizes a fixed laser 
power and a fixed imaging plane depth for image 
acquisition. Lateral resolution ranges between 3.5 
μmol/L and 1 μmol/L, resulting in a field of view of 
600 μmol/L-240 μmol/L, depending on the confocal 
probe used. Images are acquired at 12 frames/s, 
leading to real-time videos. Single video frames either 
in real time or post processed with an increased field 
of view (4 mm × 2 mm) can be reconstructed using 
a special computer algorithm (Mosaicing, Mauna Kea 
Technologies, Paris, France). Probe based CLE in IBD 
is mostly being performed by using the ColoFlex UHD 
probe, which requires a 2.8 mm working channel. 
Hence, these probes can be advanced through the 
working channel of most endoscopes used in clinical 
practice.
Both CLE-systems offer unique advantages 
and specifications and their utilization depends on 
the clinical scenario. Advantages of iCLE are its 
higher resolution, the possibility to alter the laser 
power and imaging plane depth and it also allows 
to simultaneously take biopsies and thus to directly 
compare confocal imaging with histopathological 
results. The major advantages of the pCLE system 
are its ad hoc usage in existing endoscopes and the 
possibility to perform real time video recording.
Technical characteristics of the iCLE systems and 
different CLE probes are summarized in Table 1.
The utilization of confocal endomicroscopy and 
the interpretation of images in IBD patients require 
only a short learning curve. In this regard, data from 
a prospective evaluation demonstrated that after the 
initial three examinations, performance parameters 
of CLE imaging improved with a significant decrease 
in the overall CLE procedure time and an increase in 
images in focus acquired. Further, agreement between 
CLE and histopathology improved over time with 
kappa values of 0.81 after twenty-six cases. Thus, CLE 
is a procedure that can be readily learned in a short 
time frame and that can be successfully applied in IBD 
patients[85].
In one of the first in vivo randomized trials on the 
relevance of CLE for UC surveillance, it was shown 
that by using chromoendoscopy (with methylene 
blue) together with endomicroscopy, 4.75-fold more 
neoplasias could be detected than with conventional 
colonoscopy, although 50% fewer biopsies were 
required and CLE exhibited an excellent diagnostic 
accuracy for the prediction of neoplastic changes[86]. 
In addition, using the modified Mainz confocal criteria 
for the in vivo diagnosis of adenoma-like mass (ALM) 
and DALM in a pilot study on 16 UC patients, it has 
also been shown that CLE can accurately differentiate 
between DALM and ALM with an almost perfect 
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Table 1  Technical characteristics of probe based and integrated integrated confocal laser endomicroscopy devices
Endoscope based CLE Probe based CLE
iCLE GastroFlex GastroFlexUHD ColoFlex ColoFlexUHD
Image-plane depth (μm) 0-250 70-130 55-65 70-130 55-65
Lateral resolution (μm) 0.7 3.5 1 3.5 1
Field-of-view (μm) 475 × 475 600 × 600 240 × 240 600 × 600 240 × 240
Frames per second 0.8-1.6 12 12 12 12
Magnification 1000-fold 1000-fold 1000-fold 1000-fold 1000-fold
Required operating channel (mm) ≥ 2.8 ≥ 2.8 ≥ 2.8 ≥ 2.8
Length (cm) 120 and 180 300 300 400 400
iCLE: Integrated confocal laser endomicroscopy; UHD: Ultra-high definition.
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kappa coefficient of agreement between CLE and 
histopathologic evaluation[87]. This is important since 
such an approach can significantly facilitate the clinical 
decision whether patients should receive endoluminal 
endoscopic resection or be rather referred for 
proctocolectomy[87]. Importantly, these studies utilized 
the integrated CLE system (iCLE) and subsequently, 
another pilot study on 22 UC patients demonstrated 
that surveillance in UC is also feasible with the stand-
alone CLE probe (pCLE) with reasonable diagnostic 
accuracy of the pCLE system for dysplasia detection[88]. 
These results were also confirmed by a recent meta-
analysis that included a total of fifteen studies 
involving 719 patients with either sporadic polyps or 
IBD. In this work, it has been calculated that CLE can 
distinguish neoplasms from non-neoplastic tissue in 
IBD patients with a sensitivity of 83% and specificity 
of 90%, thereby confirming that CLE can indeed 
differentiate between neoplastic and non-neoplastic 
tissue[89]. Morphologically, dysplasia on CLE is in 
general characterized by dark cells with crypt density 
attenuation, a ridged-lined irregular epithelial layer with 
loss of crypts and dilated and distorted vessels with 
elevated leakage and irregular vascular architecture. In 
contrast, inflamed mucosa is in general characterized 
by dilation of crypt openings, enlarged spaces between 
crypt, and microvascular alterations with fluorescein 
leaks into the crypt lumen therefore making the lumen 
brighter than the surrounding epithelium[78,90]. 
Apart from dysplasia detection, several reports 
have assessed the value of CLE for the real-time in 
vivo assessment of the histologic degree and the 
extent of mucosal inflammation associated with 
IBD. One of the earliest pilot studies evaluated the 
morphologic differences of the colonic mucosa between 
active and inactive UC. The crypts in UC patients with 
non-active disease were small, round and slightly 
irregular in arrangement with a small and round crypt 
lumen. In contrast, colonic crypts in active UC were 
large, variously shaped and irregular in arrangement 
whereas colonic crypts in active UC appeared large, 
variously shaped, irregularly arranged with numerous 
inflammatory cells and capillaries in the lamina 
propria[91].
These results were also confirmed by several 
other studies. A study by Li and colleagues on 73 
UC patients assessed the inflammatory activity by 
CLE with a 4-grade CLE classification system of crypt 
architecture, as well as by analysis of microvascular 
alterations and fluorescein leakage, demonstrating that 
all three parameters (crypt architecture, fluorescein 
leakage, microvasculature) showed good correlations 
with histopathology[92]. Of note, more than half of the 
patients with normal mucosa seen on conventional 
white-light endoscopy showed acute inflammation 
on histology, whereas no patients with normal 
mucosa seen on CLE showed acute inflammation 
on histology[92]. Another recently published study 
by the same group showed that CLE can be used 
to predict disease relapse in UC. In this report, UC 
patients with macroscopic normal mucosa on WLE, 
but endomicroscopic sings of active inflammation (as 
assessed by analysis of the crypt architecture with 
CLE), exhibited a significantly higher relapse rate than 
patients with non-active disease on CLE[93]. Finally, 
Buda et al[94] have further confirmed that mucosal 
changes detected in vivo by CLE in remittent UC 
patients can predict disease relapse. 
Results from our own group demonstrate that 
CLE can also reliably assess Crohn’s disease activity 
and also be utilized to differentiate Crohn’s disease 
from ulcerative colitis[95,96]. In a study on 54 patients 
with Crohn’s disease, we were able to show that 
a significantly higher proportion of patients with 
active CD had increased colonic crypt tortuosity, 
enlarged crypt lumen, microerosions, augmented 
vascularization, and increased cellular infiltrates 
within the lamina propria while, in quiescent CD, a 
significant increase in crypt and goblet cell number 
was detected compared with controls[95] and based on 
these findings, the Crohn’s Disease Endomicroscopic 
Activity Score (CDEAS) for the assessment of CD 
activity in vivo was proposed. The CDEAS does not 
only allow differentiating between quiescent CD 
and controls but also between quiescent and active 
disease and showed strong correlation to serum levels 
of the C-reactive protein[95]. In a recently published 
prospective trial on 79 IBD patients we were able 
to show that patients with CD showed significantly 
more discontinuous inflammation, more focal cry-
ptitis and more discontinuous crypt architectural 
abnormality on CLE than patients with ulcerative 
colitis. Conversely, ulcerative colitis was associated 
with severe, widespread crypt distortion, decreased 
crypt density and irregular surface and based on these 
findings, the so-called IDEA (IBD Differentiation based 
on Endomicroscopic Assessment) scoring system was 
developed exhibiting an excellent diagnostic accuracy 
when compared with the historical clinical diagnosis 
and histopathology[96].
Hence, the CLE based scoring systems such as the 
CDEAS or the IDEA appear as precise tools for the 
accurate prediction of disease severity in CD patients 
and for the differential diagnosis between CD and 
UC[95,96]. However, validation trials are highly warranted 
to proof the early results.
Another important feature for the endomicroscopic 
evaluation of inflammatory activity by CLE are the 
so-called epithelial gaps[97]. Epithelial gaps, originally 
discovered in the terminal ileum and rectum of 
patients undergoing surveillance colonoscopy, have a 
diameter of an individual epithelial cell (10 μm) and 
pathomorphologically result from shedding of epithelial 
cells. In this context it has been shown that in IL-10 
deficient mice, as a murine model of inflammatory 
bowel diseases, as well as patients with CD exhibited 
a significantly higher epithelial gap density compared 
to controls[98]. A study including 21 CD and 20 UC 
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patients with a median follow-up of 14 mo provided 
first evidence that assessment of epithelial gaps by 
CLE has important clinical relevance. In this report, 
patients with elevated gap density were at significantly 
higher risk for hospitalization or surgery[99]. Further, 
patients with elevated gap density were at increased 
risk for hospitalization and surgery and gap density 
was a significant predictor for risk of major events, 
with a hazard ratio of 1.10 associated with each 
increase of 1% in gap density. Additionally, gap density 
also correlated with IBD disease duration[99]. These 
results are corroborated by another trial on 47 UC 
and 11 CD patients in clinical and mucosal remission 
in which increased cell shedding with fluorescein 
leakage was associated with subsequent relapse 
within 12 mo after endomicroscopic examination. 
Further, endomicroscopic grading of the local barrier 
dysfunction by the so called Watson grade exhibited 
a very high specificity and good overall accuracy for 
predicting disease flares[100]. 
The role of CLE for the assessment of mucosal 
inflammation, for the prediction of therapeutic response 
and for cancer surveillance in IBD has recently been 
summarized in a systemic review[101]. In their totality, 
the above discussed studies demonstrate that CLE can 
be used to reliably assess the macro- and microscopic 
inflammatory activity in IBD patients and to obtain 
optical biopsies in real-time. Since the precise deter-
mination of mucosal inflammation is one of the most 
critical components for defining and achieving mucosal 
healing, which itself has been identified as a key 
prognostic parameter and important treatment goal in 
IBD patients[7], it is likely that CLE will become more 
important in the foreseeable future not only to facilitate 
and optimize the management and surveillance of IBD 
patients but also to prospectively identify patients that 
are under risk of experiencing a disease flare. 
ENDOCYTOSCOPY
Endocytoscopy (EC; Olympus, Tokyo, Japan) is an 
advanced imaging technology that uses contact light 
microscopy with a fixed-focus, high-power objective 
lens to allow in vivo microscopic imaging of the GI tract 
with up to 1390-fold magnification[102-104]. The depth of 
field of EC ranges from 0 to 50 μm, thereby only the 
very superficial mucosal layer can be visualized. As 
a prerequisite before image acquisition, EC requires 
thorough mucolysis (e.g., with N-acetyl-cysteine) and 
staining of the mucosa with an absorptive agent (e.g., 
methylene blue, toluidine blue, cresyl violet). Data 
from ex vivo studies suggest that optimum conditions 
for endocytoscopic observation can be obtained after 
staining with 0.25% toluidine blue in the colon, after 
60 s of exposure to the dye[105], but a combination 
of different dye agents might be required for optimal 
tissue contrast[106]. 
Similar to CLE, a probe based endocytoscopy 
system (pEC) as well as an integrated endocytoscopy 
(iEC) device are available[103]. The integrated devices 
use two different lenses and are integrated into 
endocopes for the upper (103 cm in length) and 
lower (133 cm in length) GI tract. iEC provides 
a 580x-fold image magnification and also allows 
conventional optical magnification with narrow band 
imaging capabilities. Recently, another integrated 
endocytoscope system (GIF-Y0002) was introduced 
which contains only one lens that allows to continuously 
increase the zoom from the conventional endoscopy 
level up to 380-fold (tissue field of view, 700 
mm × 600 mm) using a hand lever. Using digital 
magnification (× 1.6) in addition, the magnifying 
power can be increased to 600-fold, providing a tissue 
field of view measuring 440 mm × 380 mm[104,107]. 
With these characteristics, this new endoscope-
generation allows continous magnification from 
standard overview to the (sub)cellular level. 
For the pEC device, two different probes are 
available, providing either 450-fold (XEC 300F) or 
1390-fold (XEC 120 U) magnification[103,104]. The 
horizontal observation field is 300 μm × 300 μm (0.09 
mm2) for the 450-fold magnification probe and 120 μm 
× 120 μm for the 1390-fold magnification probe and 
both probes require an accessory channel of 3.7 mm. 
Compared with CLE, less data on the assessment 
of mucosal inflammation in IBD are available for EC. In 
an initial report on 55 UC patients, a newly introduced 
endocytoscopy scoring system (ECSS) was compared 
with Matt’s histopathological grading to evaluate the 
degree of inflammation. As shown in this report, 
assessing the shape and distance between crypts as 
well as the visibility of superficial microvessels with a 
450-fold magnification showed a strong correlation with 
Matts’ histopathological grading[108] and further, the 
ECSS showed a high reproducibility between different 
investigators[108]. Recently, our group tackled the issue 
whether EC can be used not only for the determination 
of mucosal inflammation, but also for the identification 
and visualization of single inflammatory cells. For this 
purpose, we used the probe-based EC system with 
1390-fold magnification[109]. In this report, we were 
able to demonstrate that EC is able to visualize not 
only different cellular structures within the intestinal 
mucosa such as size, arrangement, and density of cells 
but also ultrastructural patterns such as size and shape 
of nuclei and the nucleus-to-cytoplasm ratio[109]. With 
these features, EC allowed to reliably distinguish single 
inflammatory cells, namely neutrophilic, basophilic 
and eosinophilic granulocytes, and lymphocytes[109]. 
Further, concordance between endocytoscopy and 
standard histopathologic grading of disease activity 
was 100% and EC exhibited a substantial interobserver 
and almost perfect intraobserver agreement[109]. 
The detection of colitis- associated neoplasia 
or cancer with EC has not been studied to date. 
However, first evidence suggests that EC can identify 
dysplasia in aberrant crypt foci as the earliest pre-
cursor lesions of colorectal cancer in the dysplasia-
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carcinoma sequence[110] and in colonic polyps, EC is 
capable to even detect and distinguish focal high-
grade intraepithelial neoplasia[111]. Potential clinical 
applications of endocytoscopy in the upper and lower 
GI tract as well as at other mucosal surfaces have 
been recently reviewed[104].
MOLECULAR IMAGING
One limitation of the above discussed techniques is 
that, although they allow precise visualization of cellular 
structures, they are dependent on the presence of 
morphologic changes to detect pathology. In the recent 
past, techniques such as CLE have been combined with 
the utilization of fluorophores with specificity towards 
a defined molecular target, thereby enabling the 
visualization and quantification of biochemical structures 
or processes on the molecular level in real-time during 
ongoing endoscopy. This novel field of gastrointestinal 
endoscopy is referred to as “molecular imaging” or 
“in vivo immunohistochemistry” and is now a rapidly 
evolving field in gastroenterology. Since molecular 
imaging is based on the utilization of exogenous probes, 
criteria for the ideal probes utilized for molecular 
imaging in the gastrointestinal tract have been defined. 
As such, ideal probes for labeling molecular structures 
should exhibit a high diversity, high affinity binding, 
rapid binding kinetics within minutes, adequate tissue 
penetration, low immunogenicity, ability for large scale 
synthesis and florescent labelling[112]. These criteria can 
be fulfilled by different agents and so far the following 
substance classes have been successfully utilized for 
molecular imaging: antibodies, lectins, affinity peptides, 
activatable probes, nanoparticles and physiological sub-
stances[113-115].
To date, mucosal inflammation as well as cancer 
development within the GI tract has been success-
fully studied with molecular imaging, in both, mice 
and humans. Just recently, Mitsunaga and co-workers 
utilized a topically applied enzymatically activatable 
probe (gGlu-HMRG), which exhibits a fluorescent signal 
in the presence of the enzyme γ-glutamyltranspeptidase 
(GGT) to visualize cancer development by fluorescence 
colonoscopy in the AOM/DSS mouse model of colitis-
associated cancer[116]. Fluorescent lesions were de-
tected 5 min after topical administration of gGlu-
HMRG, even in small lesions, and fluorescence signal 
persisted for at least 30 min. Fluorescence guided 
biopsy revealed that all fluorescent lesions contained 
cancer or dysplasia and although microscopic inflam-
matory infiltration also had variable fluorescence, 
these signals were general approximately 10-fold lower 
than the cancerous tissue[116]. Consistent with these 
observations, other studies utilized protease-sensing 
probes, such as a cathepsin reporter probes[117,118], 
MMP-activatable probes[119], GGT substrates[116,120], or 
certain peptides[121,122] to detect and visualize intestinal 
dysplasia and polyps in murine and xenograft models. 
Furthermore, molecular targets that are upregulated 
from colorectal cancer cells and which are already 
established therapeutic targets, such as epidermal 
growth factor receptor (EGFR) or vascular endothelial 
growth factor receptor (VEGFR), have been utilized 
as fluorescent probes for the visualization and precise 
discrimination of cancer tissue[123-125].
Just recently, a first prospective human study in 
vivo on the molecular labelling of EGFR was conducted 
in 37 patients with CRC[126]. In this study, an Alexa 
488 conjugate-labeled mouse anti-hEGFR antibody 
was topically applied via a spraying catheter and 
subsequently, confocal imaging was performed. An 
EGFR-specific fluorescence signal was present in 18 out 
of 19 patients with CRC and 12 out of 18 patients with 
intestinal adenomas while normal mucosa exhibited 
no or only weak fluorescence[126]. Importantly, no side 
effects were observed during in vivo CLE imaging 
and at the 4-6 wk follow-up. Further, no human-anti 
mouse antibodies were detected serologically, although 
this aspect was assessed in serum samples of only 4 
patients[126].
A potential clinical relevance of the visualization of 
EGFR during ongoing endoscopy has been portrayed out 
in a recent study in which colon cancer xenografts were 
induced by transplanting either cetuximab-sensitive 
(HT29) or cetuximab-resistant (SW620) human CRC 
cell lines into nude mice. CLE was performed 48 h after 
injection of a fluorescently labelled cetuximab test dose 
and the initial fluorescence intensity was examined 
in relation to clinical readouts such as tumor growth, 
thriving and mortality. The initial fluorescence signal 
was significantly stronger in cetuximab-treated HT29 
tumors than in HT29 controls or cetuximab-treated 
SW620 tumors and accorded with significantly slower 
tumor progression, better overall survival and better 
physical condition. Further, cetuximab sensitivity could 
be predicted from fluorescence intensity at day 0 with 
a high positive predictive value. Importantly, molecular 
imaging was for the first time linked to an early 
prediction of response to targeted therapy in models 
of human CRC. Therefore, these results may indicate a 
promising principle for early patient stratification.
These findings were directly translated into clinical 
applications and one first clinical trial has already 
proven that the visualization of molecular targets can 
be used to make a risk stratification of IBD patients 
prior to the initiation of treatment into responders 
and non-responders, thereby allowing a prediction 
on the therapeutic success. In this landmark phase 
1 clinical trial, a FITC (fluorescein isothiocyanate) 
labeled anti-TNF antibody was manufactured under 
GMP conform conditions and topically applied during 
endoscopy to the inflamed mucosa of IBD patients 
that were naïve to anti-TNF antibody treatment. 
Subsequently, the amount of intestinal mTNF+ cells 
was quantified via CLE[127]. Importantly, patients with 
high numbers of mTNF+ cells showed significantly 
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higher short-term response rates (92%) at week 12 
upon subsequent anti-TNF therapy as compared to 
patients with low amounts of mTNF(+) cells (15%), 
despite comparable severity of mucosal inflammation 
in both patient groups. This clinical response in 
patients with high amounts of intestinal mTNF+ cells 
was sustained over a follow-up period of 1 year and 
was associated with mucosal healing observed at 
follow-up endoscopy[127].
These data were the first to provide direct evidence 
that molecular imaging with fluorescent antibodies and 
CLE can be utilized to predict therapeutic responses 
to biological treatment in Crohn’s disease prior to the 
initiation of therapy and thus might be used for an a 
priori risk stratification according to their treatment 
response. The establishment of such a personalized 
medicine approach and its integration into clinical 
routine and patient care would have a tremendous 
impact since it would allow avoiding unnecessary risk 
exposure associated with biological therapies and 
lead to a considerable economization of the treatment 
regimens at the same time.
CONCLUSION
In recent years, emerging strategies for the mana-
gement of patients with IBD have radically changed 
the role of advanced endoscopic imaging techniques 
in both, research trials and clinical practice. Image-
enhanced technologies including high-definition, 
optical magnification, and chromoendoscopy can 
remarkably refine the characterization of mucosal 
inflammation and clearly have the potential to improve 
the detection of non-polypoid dysplastic lesions in daily 
clinical practice. In addition, recent developments in 
optical biopsy techniques such as endocytoscopy and 
confocal laser endomicroscopy have made available 
the microscopic assessment of mucosal changes 
in real time during ongoing endoscopy, thereby 
predicting several histologic features with a high 
level of accuracy. The path traced by rapidly evolving 
molecular imaging technologies promises to transcend 
the known spectrum of plain morphological assessment 
of conventional luminal gastrointestinal tract to visua-
lization of molecular structures and pathways in 
IBD patients that allow individual predictions about 
therapeutic responses.
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